Key Insights on Retatrutide's Potential in Metabolic Disorders | Retatrutide News

Retatrutide, a GLP-1 agonist from Eli Lilly, is gaining attention as a promising treatment for metabolic disorders. The drug's potential impact is signi...
Market News · October 9, 2026